TransGlobe Energy Corporation Announces Third Quarter 2021 Financial and Operating Results for the Three and Nine Months Ended September 30, 2021
This Announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 (“MAR”). Upon the publication of this Announcement, this inside information is now considered to be in the public more...
Peruvian Judicial ruling confirms Company’s title to all 32 disputed Concessions
VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) — American Lithium Corp . (“American Lithium” or the “Company”) (TSX-V:LI | OTCQB:LIACF | Frankfurt:5LA1) has been made aware that the judicial ruling in relation to title more...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Live Ventures, CorMedix, Emergent BioSolutions, and Generac on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Live Ventures Incorporated (NASDAQ: LIVE), CorMedix Inc. (NASDAQ: more...
SHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing Investigations PR Newswire NEW YORK , Nov. 2, 2021 /PRNewswire/ — If you own shares in any of the companies listed more...
Identiv, Inc. (INVE) Q3 Earnings and Revenues Beat Estimates
Identiv, Inc. (INVE) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.01 per share a year ago. These figures are more...
Agile Therapeutics (AGRX) Reports Q3 Loss, Lags Revenue Estimates
Agile Therapeutics (AGRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago. These more...
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.49 per share a year ago. These more...
ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. – ADMS
ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. – ADMS ADAMAS PHARMACEUTICALS INVESTOR ALERT more...
Delta 9 Announces Renewal of its Normal Course Issuer Bid for Common Shares and Convertible Debentures
WINNIPEG, Manitoba, Nov. 02, 2021 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”) today announced that the Toronto Stock Exchange (“TSX”) has approved the renewal of the more...
Synchronoss Technologies, Inc. Reports Inducement Grants to CFO Taylor Greenwald Under Nasdaq Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. ( SNCR ) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that the more...